Uric acid in relapsing–remitting multiple sclerosis: a 2-year longitudinal study
暂无分享,去创建一个
C. Russo | A. Carotenuto | V. Brescia Morra | M. Moccia | R. Lanzillo | E. Postiglione | T. Costabile | G. Maniscalco | R. Palladino | C. De Luca Picione | M. Vastola | G. Sasso
[1] M. Arias Gómez,et al. Associated Inosine to interferon: results of a clinical trial in multiple sclerosis , 2015, Acta neurologica Scandinavica.
[2] V. Morra,et al. Uric acid: a potential biomarker of multiple sclerosis and of its disability , 2015, Clinical chemistry and laboratory medicine.
[3] F. Jacques. Defining the clinical course of multiple sclerosis: The 2013 revisions , 2015, Neurology.
[4] M. T. Pellecchia,et al. Presence and progression of non‐motor symptoms in relation to uric acid in de novo Parkinson's disease , 2015, European journal of neurology.
[5] G. Nagels,et al. The Symbol Digit Modalities Test as sentinel test for cognitive impairment in multiple sclerosis , 2014, European journal of neurology.
[6] M. T. Pellecchia,et al. Is serum uric acid related to non-motor symptoms in de-novo Parkinson's disease patients? , 2014, Parkinsonism & related disorders.
[7] F. Ashtari,et al. Serum uric acid level in patients with relapsing-remitting multiple sclerosis , 2013, Journal of Clinical Neuroscience.
[8] M. Trojano,et al. Low Serum Urate Levels Are Associated to Female Gender in Multiple Sclerosis Patients , 2012, PloS one.
[9] Kaiwen Xiao,et al. Serum uric acid levels in patients with multiple sclerosis: a meta-analysis , 2012, Neurological research.
[10] Á. Guerrero,et al. Serum uric acid levels in multiple sclerosis patients inversely correlate with disability , 2011, Neurological Sciences.
[11] Jeffrey A. Cohen,et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.
[12] C. Polman,et al. Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. , 2009, Clinical biochemistry.
[13] C. Lederer,et al. Disability as an outcome in MS clinical trials , 2008, Neurology.
[14] A. Hofman,et al. Serum uric acid and cognitive function and dementia. , 2008, Brain : a journal of neurology.
[15] Bin Zhang,et al. Serum uric acid levels of patients with multiple sclerosis and other neurological diseases. , 2008, Multiple sclerosis.
[16] H. D. Vries,et al. Therapeutic potential and biological role of endogenous antioxidant enzymes in multiple sclerosis pathology , 2007, Brain Research Reviews.
[17] S. Sorbi,et al. The Rao’s Brief Repeatable Battery and Stroop test: normative values with age, education and gender corrections in an Italian population , 2006, Multiple sclerosis.
[18] P. Pasqualetti,et al. The Symbol Digit Modalities Test - Oral version: Italian normative data. , 2006, Functional neurology.
[19] C. Knapp,et al. Serum uric acid levels in optic neuritis , 2004, Multiple sclerosis.
[20] H. Koprowski,et al. Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[21] G. Rosati,et al. Serum uric acid and multiple sclerosis , 2002, Neurological Sciences.
[22] B. Miličić,et al. Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood–brain barrier dysfunction , 2002, European journal of neurology.
[23] B. Miličić,et al. High-dose Methylprednisolone Therapy in Multiple Sclerosis Increases Serum Uric Acid Levels , 2002, Clinical chemistry and laboratory medicine.
[24] H. Koprowski,et al. Uric acid levels in patients with multiple sclerosis: analysis in mono- and dizygotic twins , 2001, Multiple sclerosis.
[25] J. Marinković,et al. Uric acid levels in sera from patients with multiple sclerosis , 2001, Journal of Neurology.
[26] L. Kappos,et al. Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis , 2000, Multiple sclerosis.
[27] W. Pryor,et al. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. , 2000, Archives of biochemistry and biophysics.
[28] H. Koprowski,et al. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood–CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[29] P. Klivényi,et al. Nonenzymatic antioxidants of blood in multiple sclerosis , 1999, Journal of Neurology.
[30] H. Koprowski,et al. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[31] O. Bagasra,et al. Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[32] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[33] D. Silberberg,et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.
[34] Muna Shakeeb Tawfiq. Rating Neurological Impairment in Multiple Sclerosis , 2016 .
[35] I. Majsterek,et al. Oxidative modification of patient's plasma proteins and its role in pathogenesis of multiple sclerosis. , 2012, Clinical biochemistry.
[36] J. Kaye,et al. Uric acid as a CNS antioxidant. , 2010, Journal of Alzheimer's disease : JAD.
[37] T. Pekmezović,et al. Cerebrospinal fluid and serum uric acid levels in patients with multiple sclerosis , 2009, Clinical chemistry and laboratory medicine.
[38] J. Hetta,et al. Hypoxanthine, xanthine, urate and creatinine concentration gradients in cerebrospinal fluid. , 1988, Upsala journal of medical sciences.